目錄:MedChemExpress LLC>>生化試劑>> KU-60019 | MCE
CAS | 925701-46-8 | 純度 | 99.43% |
---|---|---|---|
分子量 | 547.67 | 分子式 | C??H??N?O?S |
供貨周期 | 現貨 | 規格 | 5 mg |
貨號 | HY-12061 | 應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 925701-46-8
產品活性:KU-60019 is an improved ATM kinase-specific inhibitor with IC50 of 6.3 nM.
研究領域:Cell Cycle/DNA Damage | PI3K/Akt/mTOR
作用靶點:ATM/ATR
In Vitro: KU-60019 is an improved analogue of KU-55933. KU-55933 has an IC50 of 13 nM and Ki of 2.2 nM in vitro and is highly specific for the ATM kinase using a panel of 60 protein kinases. KU-60019 is an improved inhibitor of the ATM kinase with an IC50 of 6.3 nM, approximately half that of KU-55933. The IC50 values for DNA-PKcs and ATR are 1.7 and >10 μM, respectively, almost 270-and 1600-fold higher than for ATM. KU-60019 is 10-fold more effective than KU-55933 at blocking radiation-induced phosphorylation of key ATM targets in human glioma cells. In human U87 glioma cells, KU-55933 completely inhibits phosphorylation of p53 (S15) at 10 μM but not at 3 μM, whereas γ-H2AX levels are only partly reduced with 10 μM 1 h after irradiation. By comparison, 3 μM KU-60019 completely inhibits p53 phosphorylation and partial inhibits at 1 μM.
In Vivo: Despite PTEN-deficient control tumors reaching a 4-fold increase in size before PTEN wild-type controls, KU-60019-treated PTEN-deficient tumors display a statistically significant slowing in growth. This growth inhibition is especially evident at the start of the experiment (days 5-12) just after KU-60019 is administered (days 1-5).
相關產品:Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Kinase Inhibitor Library | PI3K/Akt/mTOR Compound Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Oxygen Sensing Compound Library | Glycolysis Compound Library | Cytoskeleton Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Glucose Metabolism Compound Library | Cancer Stem Cells Compound Library | Tuvusertib | Elimusertib | CGK733 | AZD1390 | Ceralasertib | AZD-7648 | KU 59403 | VE-821 | KU-55933 | ATM Inhibitor-3 | Elimusertib-d3 | ATR-IN-6 | AZD0156 | CP-466722 | Antitumor agent-28 | ATR-IN-12 | ATR-IN-18 | ATR-IN-13 | ATR-IN-5 | ATR-IN-20 | AZ32 | ATM Inhibitor-2 | Ro 90-7501 | ATR-IN-17 | ATR-IN-4 | ATR-IN-11 | AZ31 | ATR-IN-10
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
• 設有專業的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。